Skip to main content
Erschienen in: The European Journal of Health Economics 2/2017

04.02.2016 | Original Paper

Preferences for antiviral therapy of chronic hepatitis C: a discrete choice experiment

verfasst von: Axel C. Mühlbacher, John F. P. Bridges, Susanne Bethge, Ch.-Markos Dintsios, Anja Schwalm, Andreas Gerber-Grote, Matthias Nübling

Erschienen in: The European Journal of Health Economics | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten

Abstract

Background

The German Institute for Quality and Efficiency in Health Care (IQWiG) uses patient-relevant outcomes to inform decision-makers.

Objective

IQWiG conducted a pilot study to examine whether discrete choice experiments (DCEs) can be applied in health economic evaluations in Germany to identify, weight, and prioritize multiple patient-relevant outcomes, using the example of antiviral therapy for chronic hepatitis C (HCV). A further objective was to contribute to a more structured approach towards eliciting and comparing preferences across key stakeholders.

Methods

In autumn 2010, a DCE questionnaire was sent to patients with chronic HCV to estimate preferences across seven outcomes (“attributes”), including treatment efficacy [sustained viral response (SVR) at 6 months], adverse effects (flu-like symptoms, gastrointestinal symptoms, psychiatric symptoms, and skin symptoms/alopecia), and measures of treatment burden (duration of therapy, frequency of injections). A linear model and an effects coded full model were applied to assess the relative importance of the attributes.

Results

In total N = 326 patients were included. A clear preference for SVR was shown; frequency of injections and duration of therapy shared the second rank, while psychiatric symptoms ranked third. The duration of flu-like symptoms was the least important attribute.

Conclusion

Our findings indicate that it is possible to perform a DCE at the national level in a health technology assessment agency. The weighting of multiple outcomes allows an indication-specific and evidence-based measure to be used in health economic evaluations. In decision-making in health care, the approach generally allows for consideration of patient-relevant trade-offs regarding the benefits and harms of medical interventions.
Fußnoten
1
Note The present pilot study on the treatment of HCV uses attributes and outcomes that might not necessarily correspond to patient-relevant outcomes pursuant to SGB V (i.e., outcomes describing morbidity, mortality, and health-related quality of life). It cannot be concluded from the language used in the present paper that IQWiG would regard the attributes and outcomes applied to represent (patient-relevant) outcomes in the event of a benefit assessment.
 
Literatur
1.
Zurück zum Zitat Baltussen, R., et al.: Multi-criteria decision analysis to prioritize health interventions: capitalizing on first experiences. Health Policy 96(3), 262–264 (2010)CrossRefPubMed Baltussen, R., et al.: Multi-criteria decision analysis to prioritize health interventions: capitalizing on first experiences. Health Policy 96(3), 262–264 (2010)CrossRefPubMed
2.
Zurück zum Zitat Thokala, P., Duenas A.: Multiple criteria decision analysis for health technology assessment. Value in health, 15 (2012) Thokala, P., Duenas A.: Multiple criteria decision analysis for health technology assessment. Value in health, 15 (2012)
3.
Zurück zum Zitat Rotter, J.S., Foerster, D., Bridges, J.F.: The changing role of economic evaluation in valuing medical technologies. Expert Rev Pharmacoecon Outcomes Res 12(6), 711–723 (2012)CrossRefPubMed Rotter, J.S., Foerster, D., Bridges, J.F.: The changing role of economic evaluation in valuing medical technologies. Expert Rev Pharmacoecon Outcomes Res 12(6), 711–723 (2012)CrossRefPubMed
4.
Zurück zum Zitat Martin, D.K., Giacomini, M., Singer, P.A.: Fairness, accountability for reasonableness, and the views of priority setting decision-makers. Health Policy 61(3), 279–290 (2002)CrossRefPubMed Martin, D.K., Giacomini, M., Singer, P.A.: Fairness, accountability for reasonableness, and the views of priority setting decision-makers. Health Policy 61(3), 279–290 (2002)CrossRefPubMed
5.
Zurück zum Zitat Institute for Quality and Efficiency in Health Care (IQWiG): General Methods, in Version 4.1. 2013, translation based on the German document “Allgemeine Methoden” (Version 4.1): Cologne Institute for Quality and Efficiency in Health Care (IQWiG): General Methods, in Version 4.1. 2013, translation based on the German document “Allgemeine Methoden” (Version 4.1): Cologne
6.
Zurück zum Zitat Danner, M., et al.: Integrating patients’ views into health technology assessment: analytic hierarchy process (AHP) as a method to elicit patient preferences. Int J Technol Assess Health Care 27(04), 369–375 (2011)CrossRefPubMed Danner, M., et al.: Integrating patients’ views into health technology assessment: analytic hierarchy process (AHP) as a method to elicit patient preferences. Int J Technol Assess Health Care 27(04), 369–375 (2011)CrossRefPubMed
7.
Zurück zum Zitat Institut für Qualität und Wirtschaftlicheit im Gesundheitswesen (IQWiG): Wahlbasierte Conjoint-Analyse—Pilotprojekt zur Identifikation, Gewichtung und Priorisierung multipler Attribute in der Indikation Hepatitis C; IQWiG-Berichte—Nr. 227, unter Mitwirkung von, et al., Editors. 2014: Köln Institut für Qualität und Wirtschaftlicheit im Gesundheitswesen (IQWiG): Wahlbasierte Conjoint-Analyse—Pilotprojekt zur Identifikation, Gewichtung und Priorisierung multipler Attribute in der Indikation Hepatitis C; IQWiG-Berichte—Nr. 227, unter Mitwirkung von, et al., Editors. 2014: Köln
8.
Zurück zum Zitat Thurstone, L.L., A law of comparative judgment. Psychol Rev. 34, 273–286 (1927). (Reprint 1994; Psycholigical Revie, Vol. 101; No. 2; p. 266-270) Thurstone, L.L., A law of comparative judgment. Psychol Rev. 34, 273–286 (1927). (Reprint 1994; Psycholigical Revie, Vol. 101; No. 2; p. 266-270)
9.
Zurück zum Zitat Lancaster, K.J.: A new approach to consumer theory. J Polit Econ 74(2), 132–157 (1966)CrossRef Lancaster, K.J.: A new approach to consumer theory. J Polit Econ 74(2), 132–157 (1966)CrossRef
10.
Zurück zum Zitat McFadden, D., Conditional logit analysis of qualitative choice behavior. In: Zarembka, P. (ed.) Frontiers in Econometrics, pp.105–142. Academic Press, New York (1974) McFadden, D., Conditional logit analysis of qualitative choice behavior. In: Zarembka, P. (ed.) Frontiers in Econometrics, pp.105–142. Academic Press, New York (1974)
11.
Zurück zum Zitat Green, C., Gerard, K.: Exploring the social value of health-care interventions: a stated preference discrete choice experiment. Health Econ 18(8), 951–976 (2009)CrossRefPubMed Green, C., Gerard, K.: Exploring the social value of health-care interventions: a stated preference discrete choice experiment. Health Econ 18(8), 951–976 (2009)CrossRefPubMed
12.
Zurück zum Zitat Baltussen, R., et al.: Priority setting using multiple criteria: should a lung health programme be implemented in Nepal? Health Policy Plan 22(3), 178–185 (2007)CrossRefPubMed Baltussen, R., et al.: Priority setting using multiple criteria: should a lung health programme be implemented in Nepal? Health Policy Plan 22(3), 178–185 (2007)CrossRefPubMed
13.
Zurück zum Zitat de Bekker Grob, E.W., Ryan, M., Gerard, K.: Discrete choice experiments in health economics: a review of the literature. Health Econ 21(2), 145–172 (2010)CrossRefPubMed de Bekker Grob, E.W., Ryan, M., Gerard, K.: Discrete choice experiments in health economics: a review of the literature. Health Econ 21(2), 145–172 (2010)CrossRefPubMed
14.
Zurück zum Zitat Bridges, J.F.P., et al.: Conjoint analysis applications in health—a checklist: a report of the ISPOR good research practices for conjoint analysis task force. Value in Health 14(4), 403–413 (2011)CrossRefPubMed Bridges, J.F.P., et al.: Conjoint analysis applications in health—a checklist: a report of the ISPOR good research practices for conjoint analysis task force. Value in Health 14(4), 403–413 (2011)CrossRefPubMed
15.
Zurück zum Zitat Hauber, A.B., et al.: Treatment preferences and medication adherence of people with Type 2 diabetes using oral glucose-lowering agents. Diabet. Med 26(4), 416–424 (2009)CrossRefPubMed Hauber, A.B., et al.: Treatment preferences and medication adherence of people with Type 2 diabetes using oral glucose-lowering agents. Diabet. Med 26(4), 416–424 (2009)CrossRefPubMed
16.
Zurück zum Zitat Mühlbacher, A.C., et al.: Der Wert von Innovationen im Gesundheitswesen: spielen die Patientenpräferenzen eine Rolle? GRPG—R Polit Gesundheit 14(2), 53–62 (2008) Mühlbacher, A.C., et al.: Der Wert von Innovationen im Gesundheitswesen: spielen die Patientenpräferenzen eine Rolle? GRPG—R Polit Gesundheit 14(2), 53–62 (2008)
17.
Zurück zum Zitat Mühlbacher, A.C., Lincke, H.J., Nübling M.: Evaluating patients’ preferences for multiple myeloma therapy, a discrete-choice-experiment. Psycho-soc Med. 5, Doc10 (2008b) Mühlbacher, A.C., Lincke, H.J., Nübling M.: Evaluating patients’ preferences for multiple myeloma therapy, a discrete-choice-experiment. Psycho-soc Med. 5, Doc10 (2008b)
18.
Zurück zum Zitat Mühlbacher, A.C., et al.: Preferences for treatment of Attention-Deficit/Hyperactivity Disorder (ADHD): a discrete choice experiment. BMC Health Serv Res 9, 149 (2009)CrossRefPubMedPubMedCentral Mühlbacher, A.C., et al.: Preferences for treatment of Attention-Deficit/Hyperactivity Disorder (ADHD): a discrete choice experiment. BMC Health Serv Res 9, 149 (2009)CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Bridges, J.F., et al.: Things are looking up since we started listening to patients: trends in the application of conjoint analysis in health 1982–2007. Patient: Patient-Cent Outcomes Res 14(4), 273–282 (2008)CrossRef Bridges, J.F., et al.: Things are looking up since we started listening to patients: trends in the application of conjoint analysis in health 1982–2007. Patient: Patient-Cent Outcomes Res 14(4), 273–282 (2008)CrossRef
20.
Zurück zum Zitat Lancsar, E., Louviere, J.: Conducting discrete choice experiments to inform healthcare decision making: a user’s guide. PharmacoEconomics 26(8), 661–678 (2008)CrossRefPubMed Lancsar, E., Louviere, J.: Conducting discrete choice experiments to inform healthcare decision making: a user’s guide. PharmacoEconomics 26(8), 661–678 (2008)CrossRefPubMed
21.
Zurück zum Zitat Mühlbacher, A., Bethge, S., Tockhorn, A.: Präferenzmessung im gesundheitswesen: grundlagen von discrete-choice-experimenten. Gesundheitsökon Qualitätsmanag 18(4), 159–172 (2013)CrossRef Mühlbacher, A., Bethge, S., Tockhorn, A.: Präferenzmessung im gesundheitswesen: grundlagen von discrete-choice-experimenten. Gesundheitsökon Qualitätsmanag 18(4), 159–172 (2013)CrossRef
22.
Zurück zum Zitat World Health Organization: Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board. Antwerp, Belgium. J. Viral. Hepat. 6(1), 35–47 (1999) World Health Organization: Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board. Antwerp, Belgium. J. Viral. Hepat. 6(1), 35–47 (1999)
23.
Zurück zum Zitat Bayliss, M.S., et al.: A questionnaire to assess the generic and disease-specific health outcomes of patients with chronic hepatitis C. Qual Life Res 7(1), 39–55 (1998)CrossRefPubMed Bayliss, M.S., et al.: A questionnaire to assess the generic and disease-specific health outcomes of patients with chronic hepatitis C. Qual Life Res 7(1), 39–55 (1998)CrossRefPubMed
24.
Zurück zum Zitat Gutteling, J.J., et al.: Overview of research on health-related quality of life in patients with chronic liver disease. Neth J Med 65(7), 227–234 (2007)PubMed Gutteling, J.J., et al.: Overview of research on health-related quality of life in patients with chronic liver disease. Neth J Med 65(7), 227–234 (2007)PubMed
25.
Zurück zum Zitat Gutteling, J.J., et al.: Determinants of quality of life in chronic liver patients. Aliment Pharmacol Ther 23(11), 1629–1635 (2006)CrossRefPubMed Gutteling, J.J., et al.: Determinants of quality of life in chronic liver patients. Aliment Pharmacol Ther 23(11), 1629–1635 (2006)CrossRefPubMed
26.
Zurück zum Zitat Unal, G., et al.: A psychometric comparison of health-related quality of life measures in chronic liver disease. J Clin Epidemiol 54(6), 587–596 (2001)CrossRefPubMed Unal, G., et al.: A psychometric comparison of health-related quality of life measures in chronic liver disease. J Clin Epidemiol 54(6), 587–596 (2001)CrossRefPubMed
27.
Zurück zum Zitat Younossi, Z.M., et al.: Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease. Gut 45(2), 295–300 (1999)CrossRefPubMedPubMedCentral Younossi, Z.M., et al.: Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease. Gut 45(2), 295–300 (1999)CrossRefPubMedPubMedCentral
28.
Zurück zum Zitat Gralnek, I.M., et al.: Development and evaluation of the Liver Disease Quality of Life instrument in persons with advanced, chronic liver disease-the LDQOL 1.0. Am J Gastroenterol 95(12), 3552–3565 (2000)PubMed Gralnek, I.M., et al.: Development and evaluation of the Liver Disease Quality of Life instrument in persons with advanced, chronic liver disease-the LDQOL 1.0. Am J Gastroenterol 95(12), 3552–3565 (2000)PubMed
29.
Zurück zum Zitat Moser, G.: Hepatitis C und Psyche. J Gastroenterol Hepatol Erkrank 2(3), 20–22 (2004) Moser, G.: Hepatitis C und Psyche. J Gastroenterol Hepatol Erkrank 2(3), 20–22 (2004)
30.
Zurück zum Zitat Sarrazin, C., et al.: Prophylaxis, diagnosis and therapy of hepatitis C virus (HCV) infection: the German guidelines on the management of HCV infection. Z Gastroenterol 48(2), 289–351 (2010)CrossRefPubMed Sarrazin, C., et al.: Prophylaxis, diagnosis and therapy of hepatitis C virus (HCV) infection: the German guidelines on the management of HCV infection. Z Gastroenterol 48(2), 289–351 (2010)CrossRefPubMed
31.
Zurück zum Zitat Treadwell, J.R., Kearney, D., Davila, M.: Health profile preferences of hepatitis C patients. Dig Dis Sci 45(2), 345–350 (2000)CrossRefPubMed Treadwell, J.R., Kearney, D., Davila, M.: Health profile preferences of hepatitis C patients. Dig Dis Sci 45(2), 345–350 (2000)CrossRefPubMed
32.
Zurück zum Zitat Wong, J.B., et al.: Economic and clinical effects of evaluating rapid viral response to peginterferon alfa-2b plus ribavirin for the initial treatment of chronic hepatitis C. Am J Gastroenterol 98(11), 2354–2362 (2003)CrossRefPubMed Wong, J.B., et al.: Economic and clinical effects of evaluating rapid viral response to peginterferon alfa-2b plus ribavirin for the initial treatment of chronic hepatitis C. Am J Gastroenterol 98(11), 2354–2362 (2003)CrossRefPubMed
33.
Zurück zum Zitat Craxi, A.: Early virologic response with pegylated interferons. Dig Liver Dis 36(Suppl 3), 340–343 (2004)CrossRef Craxi, A.: Early virologic response with pegylated interferons. Dig Liver Dis 36(Suppl 3), 340–343 (2004)CrossRef
34.
Zurück zum Zitat Backus, L.I., et al.: Pretreatment assessment and predictors of hepatitis C virus treatment in US veterans coinfected with HIV and hepatitis C virus. J Viral Hepat 13(12), 799–810 (2006)CrossRefPubMed Backus, L.I., et al.: Pretreatment assessment and predictors of hepatitis C virus treatment in US veterans coinfected with HIV and hepatitis C virus. J Viral Hepat 13(12), 799–810 (2006)CrossRefPubMed
35.
Zurück zum Zitat Witkos, M., et al.: Predictors of antiviral therapy in a post-transfusion cohort of hepatitis C patients. Can J Gastroenterol 20(2), 107–111 (2006)CrossRefPubMedPubMedCentral Witkos, M., et al.: Predictors of antiviral therapy in a post-transfusion cohort of hepatitis C patients. Can J Gastroenterol 20(2), 107–111 (2006)CrossRefPubMedPubMedCentral
36.
Zurück zum Zitat Cotler, S.J., et al.: Patients’ values for health states associated with hepatitis C and physicians’ estimates of those values. Am J Gastroenterol 96(9), 2730–2736 (2001)CrossRefPubMed Cotler, S.J., et al.: Patients’ values for health states associated with hepatitis C and physicians’ estimates of those values. Am J Gastroenterol 96(9), 2730–2736 (2001)CrossRefPubMed
37.
Zurück zum Zitat Fraenkel, L., et al.: Patients’ preferences for treatment of hepatitis C. Med Decis Mak: Int J Soc Med Decis Mak 30(1), 45–57 (2010)CrossRef Fraenkel, L., et al.: Patients’ preferences for treatment of hepatitis C. Med Decis Mak: Int J Soc Med Decis Mak 30(1), 45–57 (2010)CrossRef
38.
Zurück zum Zitat Schackman, B.R., et al.: Quality-of-life tradeoffs for hepatitis C treatment: do patients and providers agree? Med Decis Mak 28(2), 233–242 (2008)CrossRef Schackman, B.R., et al.: Quality-of-life tradeoffs for hepatitis C treatment: do patients and providers agree? Med Decis Mak 28(2), 233–242 (2008)CrossRef
39.
Zurück zum Zitat Sawtooth Software: The CBC system for choice-based conjoint analysis. In: CBC—Technical Paper (ed.) Technical Paper Series, Sawtooth Software, Inc., Washington (2008) Sawtooth Software: The CBC system for choice-based conjoint analysis. In: CBC—Technical Paper (ed.) Technical Paper Series, Sawtooth Software, Inc., Washington (2008)
40.
Zurück zum Zitat Ryan, M., Gerard, K.: Using discrete choice experiments to value health care programmes: current practice and future research reflections. Appl Health Econ Health Policy 2(1), 55–64 (2003)PubMed Ryan, M., Gerard, K.: Using discrete choice experiments to value health care programmes: current practice and future research reflections. Appl Health Econ Health Policy 2(1), 55–64 (2003)PubMed
41.
Zurück zum Zitat Street, D., Burgess, L.: The construction of optimal stated choice experiments: theory and methods. Wiley-Interscience Series in Probability and Statistics, New Jersey (2007)CrossRef Street, D., Burgess, L.: The construction of optimal stated choice experiments: theory and methods. Wiley-Interscience Series in Probability and Statistics, New Jersey (2007)CrossRef
42.
Zurück zum Zitat Johnson, R.F., et al.: Constructing experimental designs for discrete-choice experiments: report of the ISPOR conjoint analysis experimental design good research practices task force. Value In Health 16(1), 3–13 (2013)CrossRef Johnson, R.F., et al.: Constructing experimental designs for discrete-choice experiments: report of the ISPOR conjoint analysis experimental design good research practices task force. Value In Health 16(1), 3–13 (2013)CrossRef
43.
Zurück zum Zitat Orme, B.K., Sample size issues for conjoint analysis. In: Getting Started with Conjoint Analysis, 2nd edn. pp. 57–66, Research Publishers LLC, Madison (2010) Orme, B.K., Sample size issues for conjoint analysis. In: Getting Started with Conjoint Analysis, 2nd edn. pp. 57–66, Research Publishers LLC, Madison (2010)
44.
Zurück zum Zitat Bech, M., Kjaer, T., Lauridsen, J.: Does the number of choice sets matter? Results from a web survey applying a discrete choice experiment. Health Econ 20(3), 273–286 (2011)CrossRefPubMed Bech, M., Kjaer, T., Lauridsen, J.: Does the number of choice sets matter? Results from a web survey applying a discrete choice experiment. Health Econ 20(3), 273–286 (2011)CrossRefPubMed
45.
Zurück zum Zitat Brett Hauber, A., et al.: Patient preferences and assessment of likely adherence to hepatitis C virus treatment. J Viral Hepatitis 18(9), 619–627 (2011)CrossRef Brett Hauber, A., et al.: Patient preferences and assessment of likely adherence to hepatitis C virus treatment. J Viral Hepatitis 18(9), 619–627 (2011)CrossRef
46.
Zurück zum Zitat Kauf, T.L., et al.: Patients’ willingness to accept the risks and benefits of new treatments for chronic hepatitis C virus infection. Patient: Patient-Cent Outcomes Res 5(4), 265–278 (2012) Kauf, T.L., et al.: Patients’ willingness to accept the risks and benefits of new treatments for chronic hepatitis C virus infection. Patient: Patient-Cent Outcomes Res 5(4), 265–278 (2012)
47.
Zurück zum Zitat Manns, M.P., Cornberg, M.: Sofosbuvir: the final nail in the coffin for hepatitis C? Lancet Infect Dis 13(5), 378–379 (2013)CrossRefPubMed Manns, M.P., Cornberg, M.: Sofosbuvir: the final nail in the coffin for hepatitis C? Lancet Infect Dis 13(5), 378–379 (2013)CrossRefPubMed
48.
Zurück zum Zitat Schneider, M., Zeuzem, S., Sarrazin, C.: Aktueller Stand der Hepatitis-C-Therapie. Der Gastroenterologe 8(1), 27–34 (2013)CrossRef Schneider, M., Zeuzem, S., Sarrazin, C.: Aktueller Stand der Hepatitis-C-Therapie. Der Gastroenterologe 8(1), 27–34 (2013)CrossRef
49.
Zurück zum Zitat Koch-Institut, Robert: Zur Situation bei wichtigen Infektionskrankheiten in Deutschland: virushepatitis B, C und D im Jahr 2010. Epidemiol Bull 29, 261–274 (2010) Koch-Institut, Robert: Zur Situation bei wichtigen Infektionskrankheiten in Deutschland: virushepatitis B, C und D im Jahr 2010. Epidemiol Bull 29, 261–274 (2010)
50.
Zurück zum Zitat Shepard, C.W., et al.: Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States. Pediatrics 115(5), 1220–1232 (2005)CrossRefPubMed Shepard, C.W., et al.: Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States. Pediatrics 115(5), 1220–1232 (2005)CrossRefPubMed
51.
Zurück zum Zitat Ryan, M., Gerard, K., Amaya-Amaya M., Using discrete choice experiments to value health and health care. In: The Economics of Non-Market Goods and Resources, 11, p. XIX 254 S, Springer, Dordrecht 2008 Ryan, M., Gerard, K., Amaya-Amaya M., Using discrete choice experiments to value health and health care. In: The Economics of Non-Market Goods and Resources, 11, p. XIX 254 S, Springer, Dordrecht 2008
52.
Zurück zum Zitat Institut für Qualität und Wirtschaftlicheit im Gesundheitswesen (Institute for Quality and Efficiency in Health Care) (IQWiG), Allgemeine Methoden 4.2. Köln (2015) Institut für Qualität und Wirtschaftlicheit im Gesundheitswesen (Institute for Quality and Efficiency in Health Care) (IQWiG), Allgemeine Methoden 4.2. Köln (2015)
Metadaten
Titel
Preferences for antiviral therapy of chronic hepatitis C: a discrete choice experiment
verfasst von
Axel C. Mühlbacher
John F. P. Bridges
Susanne Bethge
Ch.-Markos Dintsios
Anja Schwalm
Andreas Gerber-Grote
Matthias Nübling
Publikationsdatum
04.02.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
The European Journal of Health Economics / Ausgabe 2/2017
Print ISSN: 1618-7598
Elektronische ISSN: 1618-7601
DOI
https://doi.org/10.1007/s10198-016-0763-8

Weitere Artikel der Ausgabe 2/2017

The European Journal of Health Economics 2/2017 Zur Ausgabe